{"name":"Evopoint Biosciences Inc.","slug":"evopoint-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"XNW7201 tablets","genericName":"XNW7201 tablets","slug":"xnw7201-tablets","indication":"Other","status":"phase_1"},{"name":"XNW27011","genericName":"XNW27011","slug":"xnw27011","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"XNW5004 placebo; Chidamide","genericName":"XNW5004 placebo; Chidamide","slug":"xnw5004-placebo-chidamide","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Imipenem/Cilastatin/Relebactam","genericName":"Imipenem/Cilastatin/Relebactam","slug":"imipenem-cilastatin-relebactam","indication":"Complicated urinary tract infections (cUTI) including pyelonephritis","status":"marketed"}]}],"pipeline":[{"name":"XNW5004 placebo; Chidamide","genericName":"XNW5004 placebo; Chidamide","slug":"xnw5004-placebo-chidamide","phase":"phase_3","mechanism":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.","indications":["Relapsed or refractory peripheral T-cell lymphoma","Relapsed or refractory cutaneous T-cell lymphoma"],"catalyst":""},{"name":"XNW7201 tablets","genericName":"XNW7201 tablets","slug":"xnw7201-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Imipenem/Cilastatin/Relebactam","genericName":"Imipenem/Cilastatin/Relebactam","slug":"imipenem-cilastatin-relebactam","phase":"marketed","mechanism":"Imipenem/cilastatin/relebactam is a combination of a broad-spectrum beta-lactam antibiotic, a renal dehydropeptidase inhibitor, and a beta-lactamase inhibitor that together kill bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.","indications":["Complicated urinary tract infections (cUTI) including pyelonephritis","Complicated intra-abdominal infections (cIAI)","Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"],"catalyst":""},{"name":"XNW27011","genericName":"XNW27011","slug":"xnw27011","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVHI4MG5idDZaMUVwODRYVXZIcEhlbFlOaFpvQkVVaDdwNFMzYmdURWlkY3JHM01LX2dSY01HdXU3MG9wYjFtSUcyU2VGVGd6amJYc2tnQVpEd3R0dlE2aHhLMEF1ZXFYN29OVlRldzYtd25VdmtWWjE4a1RJNFZKbXpwNGU4ZGxDc0lmdmY1LWFTSkRmNi1TU05wTQ?oc=5","date":"2025-06-03","type":"pipeline","source":"BioWorld News","summary":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld News","headline":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNbndJbE0zZkRPaTRCZHBjRk5RSjRoZEVPc1k1WHljbllOZEZSMTk0NllWazNNbTZPem1zLXlQVDc1dms5NjR0VG4wSUJwczZHZUdMZW9kc24tUFk2Wk9lUHVZdWI3N3FTcHVTVWJQTV9QRXMwbm1HR0dmR0xQclZfVzBpdU1FNE5qdkZRc3NtdWU5TGpSeVo2VXd6YUhMajlQbzZLamM4dnl4djlQ?oc=5","date":"2025-05-30","type":"pipeline","source":"BioSpace","summary":"Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC - BioSpace","headline":"Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbkNwdHQtaTRrckZfaktQX2ZzOXRyN1VCY0xwbnVoTWFLM3otcE9nRkkxbzJsaUZlVlZ0X21MaFpBU2FtdE82Mkp2dkQ2Sy1sVkhkWU5wQ004cExCOWFiSk1YcU40U3FsNVJPRnc4a1N5cXJlMU9oYjREOW5jWGZ1R2x0bkNJZm00UEpqT1k3dWZ4aFdzRTRpQ0RHZE1ma01VSHl5SEVkMHpvZw?oc=5","date":"2025-05-30","type":"deal","source":"The Pharma Letter","summary":"Astellas inks ADC deal with Evopoint Biosciences for XNW27011 - The Pharma Letter","headline":"Astellas inks ADC deal with Evopoint Biosciences for XNW27011","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNWW5abFNzdTNqb2xnaW9Jakh0UGdYeXVBSGdlMWVUTWFrSVh4S2JIOXh2akVZR3Fia25MVGQ2RVd6eVpUOW5TM0JvUDB4NGkwRVZFSkhwWUczUTlKN2FCOG54NElRYlpZdWItMElzVVI4QWZnQWNZNG5ISXpMZ3l5cHhLR2hWaEN6T2k1QWFrYkFyRzNFN1Q0QWV1OEdtcjBfVXViMW12b0QxNDBScHI3S3R2UHc1ejJiVlBaMTVraWt4TnRnUTNDZUFBYzN4aFN3emRka3FtMk5MOVVjVWRCUU5PS0k2N3M4dE1Mb29ZRm91dXI3NVBJNlE1N3VicU84V3RfM3hyLWlyRVlBc3BiaTBDVlU1cUVRR1AyeGlyNDVZMjFKWk53S19leTRhVkU?oc=5","date":"2025-05-29","type":"deal","source":"PR Newswire","summary":"Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - PR Newswire","headline":"Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOQldhOXJicmJBYUx1ejIzdEc0UFJmSnRacURCTGduVVlJVE4yczdZcmp1MmFxRld3UHhBSXFWei1EX1lZZnRpUHJMWU9tQnY2cnp3TmNUWWlYTDZ5eVNMd3YydDAzV2x2YzJLcVFSV1owdHlPMnhZSnV1QWpUZzM3by1sckVOcHQtNHFzaFhmV0pwWVZtM1BHTkdNUW9FbklVOXoxUGU5dE9hd0poWUlN?oc=5","date":"2025-05-29","type":"deal","source":"Fierce Biotech","summary":"Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B - Fierce Biotech","headline":"Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNa3RrV041eDEzbWFGRnk1eHpsU05WYlk3N2I1SjFZcXN1bFp0U1RoSWVUbF9QSk9OM2JVZkRpaWR2T2RTZzZ1cmNENWJ2SHoyMzQtcTl4SGp2aFpBWGtCRlVZLXVGc1A0WVFGR1k4NXNibV8xbmx2VmI1Z3l2dHBiQlZkMURIb0FvVi1UR0RfLWlrZ0lEUkg4Z1YyYUdqYXNBUUVUV3hkYWlyUjIwRnoyam0yWl9PSTJnRkE5N0VBakJDVVE?oc=5","date":"2023-04-10","type":"trial","source":"BioPharma APAC","summary":"Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors. - BioPharma APAC","headline":"Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOcTU5NlUxTHE5Ql9EekhEcjVwNmZlNGxMd241dUFzbTF4YnpGR0w1S08wZDJvLTZzdnJWQWtBUDZFUXJaNkd0czBBbzk5TXJuSGdlR2EtMDliaGp6cHp1NkJ2MjBOYm5BdFo2b3RBZ3EtS3hOSHJIeklaOF9YZDRXc0VBck5XR0d6aTg1czZVSWNjS2gwV0tjQVRlUVZTRUZ1aWFxM1pGendQOURnbmV5aVhMTmxtLXM?oc=5","date":"2023-01-06","type":"deal","source":"Business Wire","summary":"METiS Announces License Agreement with Evopoint Biosciences - Business Wire","headline":"METiS Announces License Agreement with Evopoint Biosciences","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_1":2,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}